MARLBOROUGH, Mass.–(EMWNews)–Sepracor Inc. (Nasdaq: SEPR) today

announced its intention to fully support the Pharmaceutical Research and

Manufacturers of America’s (PhRMA) updated and

enhanced Code on Interactions with Healthcare Professionals (PhRMA

Code). The purpose of the revised PhRMA Code includes addressing

interactions with respect to marketed pharmaceutical products and

related pre-launch activities, and the industry’s

relationships with clinical investigators and others as they relate to

the clinical research process.

“Sepracor has always been committed to

responsible and ethical interactions with healthcare professionals,”

said Adrian Adams, President and Chief Executive Officer of Sepracor. “This

new PhRMA Code serves to underscore the importance of maintaining an

appropriate, two-way, educational or informational communication between

healthcare professionals and pharmaceutical industry representatives.

During the next six months, we intend to update our policies and

procedures to ensure compliance with not only the letter, but the

spirit, of the standards set forth in the new PhRMA Code.”

About Sepracor

Sepracor Inc. is a research-based pharmaceutical company dedicated to

treating and preventing human disease by discovering, developing and

commercializing innovative pharmaceutical products that are directed

toward serving large and growing markets and unmet medical needs.

Sepracor’s drug development program has yielded a portfolio of

pharmaceutical products and candidates with a focus on respiratory and

central nervous system disorders. Currently marketed products include

LUNESTA^® brand

eszopiclone, XOPENEX^®

brand levalbuterol HCl Inhalation Solution, XOPENEX HFA^®

brand levalbuterol tartrate Inhalation Aerosol, BROVANA^®

brand arformoterol tartrate Inhalation Solution and OMNARIS^™

brand ciclesonide Nasal Spray. Sepracor’s corporate headquarters are

located in Marlborough, Massachusetts.

LUNESTA, XOPENEX, XOPENEX HFA and BROVANA are registered trademarks of

Sepracor Inc. OMNARIS is a trademark of Nycomed GmbH.

For a copy of this release or any recent release,

visit Sepracor’s web site at www.sepracor.com.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions